The government-appointed committee investigating claims that four cough syrups made in India may have led&nbsp;to the deaths of 66 children in The Gambia has found that the clinical data provided by the WHO so far is insufficient to identify the aetiology.

Drugs Controller General of India (DCGI) V G Somani said that the WHO has been informed about this on Saturday.

On October 13, the WHO's Rutendo Kuwana wrote to the DCGI to inquire about the status of the inquiry into Maiden Pharmaceuticals, the Sonipat-based maker of the four cough syrups.

In response to an email, Dr&nbsp;Somani said on Saturday that the Union ministry of health has established a committee of technical specialists to review and analyse the specifics of the adverse event reports and any relevant information supplied or to be shared by WHO, and to recommend subsequent action.

Also read |&nbsp;<a href="https://www.wionews.com/india-news/india-kashmir-hosts-its-first-ever-international-bikers-expedition-525131">India: Kashmir hosts its first-ever international bikers’ expedition</a>

In its first meeting, the four-member committee, which is led by Dr Y. K. Gupta, Vice Chairperson of the Standing National Committee on Medicines, reviewed the reports and communications that have been so far received from the WHO. The committee also made a number of observations.

Mentioning the observations, Dr Somani said, "The clinical features and the treatment received by the children as shared by <a href="https://www.wionews.com/science/signs-of-dementia-can-be-detected-at-least-nine-years-prior-to-official-diagnosis-says-study-525111">WHO</a> so far are inadequate to determine the aetiology."

The specifics of the initial illness, <a href="https://www.wionews.com/science/scientists-have-successfully-implanted-and-integrated-human-brain-cells-into-newborn-rats-525434">signs</a> and symptoms, length of anura in the cases, results of laboratory tests including different markers and parameters, investigations for diethylene glycol and ethylene glycol on critical patient samples, treatment received prior to and following hospitalisation at the tertiary hospital in Gambia, treatment received prior to and following acute kidney injury was suspected, and reasons therefore, names and brands of the drugs,&nbsp;he said.

Dr Somani added that if a verbal autopsy was performed, the WHO might share a complete report.

Dr&nbsp;Somani has also enquired about the quantity of biological samples taken from children who had clinical symptoms similar to acute renal injury as well as the quantity of stool samples taken and analysed.

He also wanted information on the circumstances in which these items were used, as well as information on the product samples that were tested and found to be free of EG and DEG (as well as their composition).&nbsp;

"You are therefore requested to share the report on causal relations along with above details, as observed by the said Technical Committee at the earliest for further examination and follow up action at our level," he wrote.

"The manufacturing site has been inspected, test reports of sampled products from the laboratory are awaited and all the manufacturing activities of the manufacturer in question have been stopped," he said.

The four-person expert panel was set up by the Union health ministry on Wednesday to look into the specifics and adverse event reports regarding the deaths of 66 children in Gambia that may have been connected to four cough syrups produced by Maiden Pharmaceuticals' Sonipat facility. These reports were received from the WHO.

After reviewing and analysing the reports of adverse events, the causal relationship, and all relevant information that has already been shared by or will be shared by the World Health Organization, the committee will recommend a further course of action to the Drugs Controller General of India (DCGI).

WHO has not yet disclosed the connection between the deaths. To date, the WHO has provided CDSCO with the certificates of analysis, images, and summaries of each product sampled.

According to official sources, the WHO has announced that it is doing more inquiry.

While the Haryana State Drug Controller on October 7 issued Maiden Pharmaceuticals a show cause notice requesting an explanation of the "many contraventions" found during a recent inspection within a week or risk licence suspension or cancellation, the Haryana government on October 11 issued an order to cease all manufacturing operations of the company with immediate effect.

Official sources reported that the WHO has declared that it is doing additional inquiry.

(With inputs from agencies)

WATCH WION LIVE HERE:

<iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed" style="width:100%;max-width:560px;" width="560"></iframe>

The government-appointed committee investigating claims that four cough syrups made in India may have led to the deaths of 66 children in The Gambia has found that the clinical data provided by the WHO so far is insufficient to identify the aetiology.

The government-appointed committee investigating claims that four cough syrups made in India may have led to the deaths of 66 children in The Gambia has found that the clinical data provided by the WHO so far is insufficient to identify the aetiology. Drugs Controller General of India (DCGI) V G Somani said that the WHO has been informed about this on Saturday. On October 13, the WHO's Rutendo Kuwana wrote to the DCGI to inquire about the status of the inquiry into Maiden Pharmaceuticals, the Sonipat-based maker of the four cough syrups. In response to an email, Dr Somani said on Saturday that the Union ministry of health has established a committee of technical specialists to review and analyse the specifics of the adverse event reports and any relevant information supplied or to be shared by WHO, and to recommend subsequent action. Also read | India: Kashmir hosts its first-ever international bikers’ expedition In its first meeting, the four-member committee, which is led by Dr Y. K. Gupta, Vice Chairperson of the Standing National Committee on Medicines, reviewed the reports and communications that have been so far received from the WHO. The committee also made a number of observations. Mentioning the observations, Dr Somani said, "The clinical features and the treatment received by the children as shared by WHO so far are inadequate to determine the aetiology." The specifics of the initial illness, signs and symptoms, length of anura in the cases, results of laboratory tests including different markers and parameters, investigations for diethylene glycol and ethylene glycol on critical patient samples, treatment received prior to and following hospitalisation at the tertiary hospital in Gambia, treatment received prior to and following acute kidney injury was suspected, and reasons therefore, names and brands of the drugs, he said. Dr Somani added that if a verbal autopsy was performed, the WHO might share a complete report. Dr Somani has also enquired about the quantity of biological samples taken from children who had clinical symptoms similar to acute renal injury as well as the quantity of stool samples taken and analysed. He also wanted information on the circumstances in which these items were used, as well as information on the product samples that were tested and found to be free of EG and DEG (as well as their composition). "You are therefore requested to share the report on causal relations along with above details, as observed by the said Technical Committee at the earliest for further examination and follow up action at our level," he wrote. "The manufacturing site has been inspected, test reports of sampled products from the laboratory are awaited and all the manufacturing activities of the manufacturer in question have been stopped," he said. The four-person expert panel was set up by the Union health ministry on Wednesday to look into the specifics and adverse event reports regarding the deaths of 66 children in Gambia that may have been connected to four cough syrups produced by Maiden Pharmaceuticals' Sonipat facility. These reports were received from the WHO. After reviewing and analysing the reports of adverse events, the causal relationship, and all relevant information that has already been shared by or will be shared by the World Health Organization, the committee will recommend a further course of action to the Drugs Controller General of India (DCGI). WHO has not yet disclosed the connection between the deaths. To date, the WHO has provided CDSCO with the certificates of analysis, images, and summaries of each product sampled. According to official sources, the WHO has announced that it is doing more inquiry. While the Haryana State Drug Controller on October 7 issued Maiden Pharmaceuticals a show cause notice requesting an explanation of the "many contraventions" found during a recent inspection within a week or risk licence suspension or cancellation, the Haryana government on October 11 issued an order to cease all manufacturing operations of the company with immediate effect. Official sources reported that the WHO has declared that it is doing additional inquiry. (With inputs from agencies) WATCH WION LIVE HERE:

India committee tells WHO: Information on 'killer' cough syrups 'inadequate'

Authorities in India have halted production at Median Pharmaceuticals after the World Health Organization issued an advisory against this company's four cough syrups.

India: After WHO's alert, government's crackdown on Maiden pharma

Indian authorities have halted production at the Maiden Pharmaceuticals after WHO issued an advisory against cough syrups that lead to a dozen of children's deaths in Gambia last week.

Gambia cough syrup deaths: After WHO's alert, Indian govt's crackdown on Maiden Pharma

Anil Vij, the minister of health for Haryana, announced on Wednesday that the state has decided to "completely stop" Maiden Pharmaceuticals Limited of Sonipat from producing any further drugs.

The government has also issued a notice to the company after at least “12 flaws were found in the production of medicines during the joint inspection conducted by the drugs department teams of the Centre and state government”.

The development follows a World Health Organization (WHO) caution about four cough syrups produced by the firm following child fatalities in The Gambia.&nbsp;

Following the WHO notice, the Haryana government had already sent samples of the four cough syrups made by the pharmaceutical business to the Central Drugs Laboratory (CDL), located in Kolkata.

“The report is awaited and further action shall be taken accordingly. But, in the joint inspection conducted by the teams of the central and state drugs department, 12 flaws were found. Thus, we have decided that the total production of this pharmaceutical company should be stopped. A notice has been issued to the company,” Vij said.

Also Read:&nbsp;<a href="https://www.wionews.com/photos/in-pics-breathtaking-images-from-wildlife-photographer-of-the-year-2022-524779">In pics: Breathtaking images from wildlife photographer of the year 2022</a>

On October 6, Haryana demanded a probe into claims that the company's Sonipat factory was producing tainted cough syrups.&nbsp;

The samples were taken, and they were forwarded to Kolkata for additional analysis.&nbsp;

The Drugs Controller General of India, India's drug enforcement agency, has also opened an investigation.

(with inputs from agencies)

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1  width=&quot;100%&quot;"></iframe>

Anil Vij, the minister of health for Haryana, announced on Wednesday that the state has decided to "completely stop" Maiden Pharmaceuticals Limited of Sonipat from producing any further drugs.

Anil Vij, the minister of health for Haryana, announced on Wednesday that the state has decided to "completely stop" Maiden Pharmaceuticals Limited of Sonipat from producing any further drugs. The government has also issued a notice to the company after at least “12 flaws were found in the production of medicines during the joint inspection conducted by the drugs department teams of the Centre and state government”. The development follows a World Health Organization (WHO) caution about four cough syrups produced by the firm following child fatalities in The Gambia. Following the WHO notice, the Haryana government had already sent samples of the four cough syrups made by the pharmaceutical business to the Central Drugs Laboratory (CDL), located in Kolkata. “The report is awaited and further action shall be taken accordingly. But, in the joint inspection conducted by the teams of the central and state drugs department, 12 flaws were found. Thus, we have decided that the total production of this pharmaceutical company should be stopped. A notice has been issued to the company,” Vij said. Also Read: In pics: Breathtaking images from wildlife photographer of the year 2022 On October 6, Haryana demanded a probe into claims that the company's Sonipat factory was producing tainted cough syrups. The samples were taken, and they were forwarded to Kolkata for additional analysis. The Drugs Controller General of India, India's drug enforcement agency, has also opened an investigation. (with inputs from agencies)

India orders pharma firm to stop production after Gambia infant deaths

Police in Gambia on Saturday announced they were launching an investigation into the deaths of dozens of children, amid growing concern over imported medicines.&nbsp;Following the deaths of 66 children, most from acute kidney failure, police said in a statement they were putting senior officers on the investigation.

India is investigating cough syrups made by a local pharmaceutical company after the World Health Organisation said they could be responsible for the deaths.

Watch |&nbsp;Gravitas: Gambia Cough Syrup deaths: All you need to know

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-gambia-cough-syrup-deaths-all-you-need-to-know-523133/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

President Adama Barrow authorised the health authorities "to suspend the license of the suspected... importer" involved in the case, his office said on Saturday evening.&nbsp;

The foreign ministry was to communicate "his government's most profound concern" to the Indian embassy, it added.

Barrow on Friday promised to boost health measures including better quality control over imported medicines.

Also read |&nbsp;<a href="https://www.wionews.com/india-news/cough-syrup-case-who-yet-to-provide-exact-one-to-one-casual-relation-of-deaths-in-gambia-522919">Gambia cough syrup row:&nbsp;Indian body says WHO yet to provide 'one to one causal relation of deaths'</a>

He said the government would leave "no stone unturned" to get to the bottom of the incident.

The WHO on Wednesday issued an alert over four cough and cold syrups made by Maiden Pharmaceuticals in India over possible links to the deaths.

Laboratory testing had found unacceptable levels of potentially life-threatening contaminants, the WHO said, adding that the products may have been distributed beyond the West African country.

Also read |&nbsp;​​​​​​​<a href="https://www.wionews.com/world/who-alleges-made-in-india-cough-syrup-linked-to-death-of-66-kids-in-gambia-probe-underway-522809">WHO alleges 'made in India' cough syrup linked to death of 66 kids in Gambia, probe underway</a>

Gambian health authorities had on September 23 ordered a recall of all medicines containing paracetamol or promethazine syrup.

Barrow announced a raft of measures to avoid future tragedies, including the creation of "a quality control national laboratory for drugs and food safety".

He also promised to update the nation's drugs-related laws to ensure regulation could prevent any such incidents in the future.&nbsp;He praised the work of the health ministry in preventing further deaths.&nbsp;He said the outbreak was "now under control, with only two cases reported in the last two weeks".

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

Police in Gambia on Saturday announced they were launching an investigation into the deaths of dozens of children, amid growing concern over imported medicines. Following the deaths of 66 children, most from acute kidney failure, police said in a statement they were putting senior officers on the investigation.

Police in Gambia on Saturday announced they were launching an investigation into the deaths of dozens of children, amid growing concern over imported medicines. Following the deaths of 66 children, most from acute kidney failure, police said in a statement they were putting senior officers on the investigation. India is investigating cough syrups made by a local pharmaceutical company after the World Health Organisation said they could be responsible for the deaths. Watch | Gravitas: Gambia Cough Syrup deaths: All you need to know President Adama Barrow authorised the health authorities "to suspend the license of the suspected... importer" involved in the case, his office said on Saturday evening. The foreign ministry was to communicate "his government's most profound concern" to the Indian embassy, it added. Barrow on Friday promised to boost health measures including better quality control over imported medicines. Also read | Gambia cough syrup row: Indian body says WHO yet to provide 'one to one causal relation of deaths' He said the government would leave "no stone unturned" to get to the bottom of the incident. The WHO on Wednesday issued an alert over four cough and cold syrups made by Maiden Pharmaceuticals in India over possible links to the deaths. Laboratory testing had found unacceptable levels of potentially life-threatening contaminants, the WHO said, adding that the products may have been distributed beyond the West African country. Also read | WHO alleges 'made in India' cough syrup linked to death of 66 kids in Gambia, probe underway Gambian health authorities had on September 23 ordered a recall of all medicines containing paracetamol or promethazine syrup. Barrow announced a raft of measures to avoid future tragedies, including the creation of "a quality control national laboratory for drugs and food safety". He also promised to update the nation's drugs-related laws to ensure regulation could prevent any such incidents in the future. He praised the work of the health ministry in preventing further deaths. He said the outbreak was "now under control, with only two cases reported in the last two weeks". WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Gambia police launch enquiry into cough syrup related deaths, President says outbreak 'now under control'

WHO has sounded a global alert over the deaths of 66 children in the Gambia allegedly due to unsafe cough syrups. It says the products caused kidney injuries in children. Where were the products manufactured? Molly Gambhir brings you a report.

Gravitas: Gambia Cough Syrup deaths: All you need to know

The World Health Organization (WHO) is yet to provide the exact "one to one causal&nbsp;relation of deaths," said sources at the Indian drugs standards body after the UN agency linked deaths of 66 children in Gambia to India-made cough syrups, media reports said.&nbsp;

"While all required steps will be taken, as a robust regulatory authority, WHO has been requested to share with CDSCO at the earliest the report on the establishment of a causal relation to the deaths with the medical products in question, photographs of labels/products, etc," PTI quoted an official source as saying.&nbsp;CDSCO stands for the Central Drugs Standard Control Organisation.

<a href="https://www.wionews.com/india-news/india-registers-decline-in-female-infant-mortality-rate-smriti-irani-522839">Also read |&nbsp;India registers decline in female infant mortality rate: Minister Smriti Irani</a>

The WHO had issued a warning on Wednesday (October 6) against allegedly "contaminated" cough syrups manufactured in Haryana by Maiden Pharmaceuticals Limited as a possible cause of deaths in the West African nation.

The WHO earlier informed the Drugs Controller General of India that it is providing medical assistance to Gambia. After the deaths were reported, the health organisation suspected the use of medicines to be the prime reason for the deaths. It highlighted that medicines might have been contaminated with diethylene glycol or ethylene glycol and later confirmed the samples to be positive as well.&nbsp;

As per WHO's tentative result, four out of the 23 samples found diethylene glycol or ethylene glycol.

The CDSCO said that it responded to the WHO immediately and took up the matter with the authorities.&nbsp;

<a href="https://www.wionews.com/world/who-alleges-made-in-india-cough-syrup-linked-to-death-of-66-kids-in-gambia-probe-underway-522809">Also read |&nbsp;WHO alleges 'made in India' cough syrup linked to death of 66 kids in Gambia, probe underway</a>

The source further added that a detailed investigation was launched into the matter with the Haryana State Drugs Controller.&nbsp;

WHO has also confirmed that soon India will share the certificate of analysis.

(With inputs from agencies)

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

The World Health Organization (WHO) is yet to provide the exact "one to one causal relation of deaths," said sources at the Indian drugs standards body after the UN agency linked deaths of 66 children in Gambia to India-made cough syrups, media reports said.

The World Health Organization (WHO) is yet to provide the exact "one to one causal relation of deaths," said sources at the Indian drugs standards body after the UN agency linked deaths of 66 children in Gambia to India-made cough syrups, media reports said. "While all required steps will be taken, as a robust regulatory authority, WHO has been requested to share with CDSCO at the earliest the report on the establishment of a causal relation to the deaths with the medical products in question, photographs of labels/products, etc," PTI quoted an official source as saying. CDSCO stands for the Central Drugs Standard Control Organisation. Also read | India registers decline in female infant mortality rate: Minister Smriti Irani The WHO had issued a warning on Wednesday (October 6) against allegedly "contaminated" cough syrups manufactured in Haryana by Maiden Pharmaceuticals Limited as a possible cause of deaths in the West African nation. The WHO earlier informed the Drugs Controller General of India that it is providing medical assistance to Gambia. After the deaths were reported, the health organisation suspected the use of medicines to be the prime reason for the deaths. It highlighted that medicines might have been contaminated with diethylene glycol or ethylene glycol and later confirmed the samples to be positive as well. As per WHO's tentative result, four out of the 23 samples found diethylene glycol or ethylene glycol. The CDSCO said that it responded to the WHO immediately and took up the matter with the authorities. Also read | WHO alleges 'made in India' cough syrup linked to death of 66 kids in Gambia, probe underway The source further added that a detailed investigation was launched into the matter with the Haryana State Drugs Controller. WHO has also confirmed that soon India will share the certificate of analysis. (With inputs from agencies) WATCH WION LIVE HERE

Gambia cough syrup row: Indian body says WHO yet to provide 'one to one causal relation of deaths'

The World Health Organization (WHO) on Wednesday (October 5) said that it is investigating "contaminated" medicines, majorly for pediatric use, which are found to contain toxic chemicals.&nbsp;

WHO has issued a warning that they could be linked to the deaths of 66 children in the west African nation of The Gambia.&nbsp;

The cough and cold syrups are produced by Maiden Pharmaceuticals Limited in India.&nbsp;

In a series of tweets, the WHO, citing its Director-General Tedros Adhanom Ghebreyesus, said: "WHO has today issued a medical product alert for four contaminated medicines identified in #Gambia that have been potentially linked with acute kidney injuries and 66 deaths among children. The loss of these young lives is beyond heartbreaking for their families."&nbsp;

ALSO READ |&nbsp;<a href="https://www.wionews.com/world/singapore-makes-biggest-ever-seizure-of-rhino-horn-worth-us830000-522794">Singapore makes biggest ever seizure of rhino horn worth US$830,000</a>&nbsp;

It added, "The four medicines are cough and cold syrups produced by Maiden Pharmaceuticals Limited, in India. WHO is conducting further investigation with the company and regulatory authorities in India."&nbsp;

Tedros also said that WHO was "conducting further investigation with the company and regulatory authorities in India."&nbsp;

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
"The four medicines are cough and cold syrups produced by Maiden Pharmaceuticals Limited, in India. WHO is conducting further investigation with the company and regulatory authorities in India"-<a href="https://twitter.com/DrTedros?ref_src=twsrc%5Etfw">@DrTedros</a> <a href="https://t.co/PceTWc836t">https://t.co/PceTWc836t</a>
— World Health Organization (WHO) (@WHO) <a href="https://twitter.com/WHO/status/1577650046518104065?ref_src=twsrc%5Etfw">October 5, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

As per the alert issued by WHO, the four products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup.&nbsp;

WHO mentioned that "to date, the stated manufacturer has not provided guarantees to WHO on the safety and quality of these products." It further added that laboratory analysis of samples of the products "confirms that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants."&nbsp;

Data Lab | <a href="https://www.wionews.com/india-news/data-lab-indias-supreme-court-legalises-abortion-regardless-of-marital-status-522735">India’s Supreme Court gives nod to abortion, regardless of marital status</a>&nbsp;

The warning states that the toxic substances and can be fatal to humans. The toxic effect "can include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state and acute kidney injury which may lead to death."&nbsp;

WHO said that information received from India's Central Drugs Standard Control Organisation indicated that the manufacturer had only supplied the contaminated medications to The Gambia.&nbsp;

WATCH WION LIVE HERE&nbsp;

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

The World Health Organization (WHO) on Wednesday (October 5) said that it is investigating "contaminated" medicines, majorly for pediatric use, which are found to contain toxic chemicals.

The World Health Organization (WHO) on Wednesday (October 5) said that it is investigating "contaminated" medicines, majorly for pediatric use, which are found to contain toxic chemicals. WHO has issued a warning that they could be linked to the deaths of 66 children in the west African nation of The Gambia. The cough and cold syrups are produced by Maiden Pharmaceuticals Limited in India. In a series of tweets, the WHO, citing its Director-General Tedros Adhanom Ghebreyesus, said: "WHO has today issued a medical product alert for four contaminated medicines identified in #Gambia that have been potentially linked with acute kidney injuries and 66 deaths among children. The loss of these young lives is beyond heartbreaking for their families." ALSO READ | Singapore makes biggest ever seizure of rhino horn worth US$830,000 It added, "The four medicines are cough and cold syrups produced by Maiden Pharmaceuticals Limited, in India. WHO is conducting further investigation with the company and regulatory authorities in India." Tedros also said that WHO was "conducting further investigation with the company and regulatory authorities in India." "The four medicines are cough and cold syrups produced by Maiden Pharmaceuticals Limited, in India. WHO is conducting further investigation with the company and regulatory authorities in India"-@DrTedros https://t.co/PceTWc836t — World Health Organization (WHO) (@WHO) October 5, 2022 × As per the alert issued by WHO, the four products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup. WHO mentioned that "to date, the stated manufacturer has not provided guarantees to WHO on the safety and quality of these products." It further added that laboratory analysis of samples of the products "confirms that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants." Data Lab | India’s Supreme Court gives nod to abortion, regardless of marital status The warning states that the toxic substances and can be fatal to humans. The toxic effect "can include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state and acute kidney injury which may lead to death." WHO said that information received from India's Central Drugs Standard Control Organisation indicated that the manufacturer had only supplied the contaminated medications to The Gambia. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

WHO alleges 'made in India' cough syrup linked to death of 66 kids in Gambia, probe underway

The Sleepy chicken challenge has been deemed a 'recipe for danger' by the FDA. The challenge involves cooking chicken in NyQuil, a cough syrup used for common cold. Priyanka Sharma tells you why it's problematic.

Gravitas: Why the 'Sleepy Chicken' challenge is dangerous

cough-syrup

Cough Syrup, News on Cough Syrup, stories on Cough Syrup, articles on Cough Syrup, Cough Syrup stories at Wion, Cough Syrup news, Cough Syrup latest news